Synthesis of chitosan polyethylene glycol antibody complex for delivery of Imatinib in lung cancer cell lines.
Humans
Imatinib Mesylate
/ pharmacology
Chitosan
/ chemistry
Polyethylene Glycols
/ chemistry
Lung Neoplasms
/ drug therapy
A549 Cells
Apoptosis
/ drug effects
Antineoplastic Agents
/ pharmacology
Antibodies, Monoclonal, Humanized
/ pharmacology
Drug Carriers
/ chemistry
Cell Line, Tumor
Carcinoma, Non-Small-Cell Lung
/ drug therapy
A 549 cell line
Imatinib
NSCLC treatment
Ph sensitive
Ramucirumab antibody
chitosan nanoparticle
Journal
Journal of biochemical and molecular toxicology
ISSN: 1099-0461
Titre abrégé: J Biochem Mol Toxicol
Pays: United States
ID NLM: 9717231
Informations de publication
Date de publication:
Aug 2024
Aug 2024
Historique:
revised:
21
03
2024
received:
18
01
2024
accepted:
18
07
2024
medline:
29
7
2024
pubmed:
29
7
2024
entrez:
29
7
2024
Statut:
ppublish
Résumé
Lung cancer is known as the most common cancer. Although the Ramucirumab antibody is a second-line treatment for lung cancer, the high interstitial fluid pressure limits the antibody's performance. In this way, Imatinib is a chemotherapeutic drug to reduce the interstitial fluid pressure. Up to now, unfortunately, both Ramucirumab and imatinib have not been reported in one nanosystem for cancer therapy. To fulfill this shortcoming, this paper aims to design a chitosan nanocarrier that loads imatinib and attaches to Ramucirumab for selective bonding to A549. Therefore, this paper aims to develop a polymeric nanosystem for non-small cell lung cancer (NSCLC) treatment. In first, the chitosan polyethylene glycol nanoparticle is synthesized, loaded with imatinib, and then targeted using Ramucirumab. Afterwards, the CS-PEG-Ab-Im by FTIR, TEM, DLS, zeta potential, and TGA techniques are characterized. The size of CS-PEG-Ab-Im was 25-30 nm, its surface charge was 13.1 mV, and the shape of CS-PEG-Ab-Im was nearly spherical and cylindrical. The therapeutic potential of CS-PEG-Ab-Im was assessed using the A549 cell line. According to the obtained results, the cell viability was 48% after 48 h of treatment of A549 cells using the IC50 concentration of CS-PEG-Ab-Im (100 nanomolar). Moreover, the apoptosis and cell cycle arrest percentages were increased by 3 and 6 times, respectively, as compared to free imatinib. Furthermore, the release rate of imatinib from CS-PEG-Ab-Im in an acidic medium was 17% during 1 h, indicating five times the imatinib release in the natural medium. Eventually, the result of flow cytometry indicates the more apoptotic effect of nanosystem to free imatinib and CS-PEG-Ab. Besides, cell arresting result exhibits the CS-PEG-Ab-Im and causes cell arrested at G1 by %8.17. Thus, it can be concluded that CS-PEG-Ab-Im can be an ideal nanosystem in NSCLC treatment.
Substances chimiques
Imatinib Mesylate
8A1O1M485B
Chitosan
9012-76-4
Polyethylene Glycols
3WJQ0SDW1A
Antineoplastic Agents
0
Antibodies, Monoclonal, Humanized
0
Drug Carriers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e23787Informations de copyright
© 2024 Wiley Periodicals LLC.
Références
A. M. Frankell, M. Dietzen, M. Al Bakir, E. L. Lim, T. Karasaki, S. Ward, S. Veeriah, E. Colliver, A. Huebner, A. Bunkum, M. S. Hill, K. Grigoriadis, D. A. Moore, J. R. M. Black, W. K. Liu, K. Thol, O. Pich, T. B. K. Watkins, C. Naceur‐Lombardelli, D. E. Cook, R. Salgado, G. A. Wilson, C. Bailey, M. Angelova, R. Bentham, C. Martínez‐Ruiz, C. Abbosh, A. G. Nicholson, J. Le Quesne, D. Biswas, R. Rosenthal, C. Puttick, S. Hessey, C. Lee, P. Prymas, A. Toncheva, J. Smith, W. Xing, J. Nicod, G. Price, K. M. Kerr, B. Naidu, G. Middleton, K. G. Blyth, D. A. Fennell, M. D. Forster, S. M. Lee, M. Falzon, M. Hewish, M. J. Shackcloth, E. Lim, S. Benafif, P. Russell, E. Boleti, M. G. Krebs, J. F. Lester, D. Papadatos‐Pastos, T. Ahmad, R. M. Thakrar, D. Lawrence, N. Navani, S. M. Janes, C. Dive, F. H. Blackhall, Y. Summers, J. Cave, T. Marafioti, J. Herrero, S. A. Quezada, K. S. Peggs, R. F. Schwarz, P. Van Loo, D. M. Miedema, N. J. Birkbak, C. T. Hiley, A. Hackshaw, S. Zaccaria, J. Le Quesne, P. Van Loo, A. Bajaj, A. Nakas, A. Sodha‐Ramdeen, K. Ang, M. Tufail, M. F. Chowdhry, M. Scotland, R. Boyles, S. Rathinam, C. Wilson, D. Marrone, S. Dulloo, G. Matharu, J. A. Shaw, J. Riley, L. Primrose, H. Cheyne, M. Khalil, S. Richardson, T. Cruickshank, K. Gilbert, A. J. Patel, A. Osman, C. Lacson, G. Langman, H. Shackleford, M. Djearaman, S. Kadiri, A. Leek, J. D. Hodgkinson, N. Totten, A. Montero, E. Smith, E. Fontaine, F. Granato, H. Doran, J. Novasio, K. Rammohan, L. Joseph, P. Bishop, R. Shah, S. Moss, V. Joshi, P. Crosbie, F. Gomes, K. Brown, M. Carter, A. Chaturvedi, L. Priest, P. Oliveira, C. R. Lindsay, A. Clipson, J. Tugwood, A. Kerr, D. G. Rothwell, E. Kilgour, H. J. W. L. Aerts, T. L. Kaufmann, Z. Szallasi, J. Kisistok, M. Sokac, M. Diossy, J. Demeulemeester, A. Stewart, A. Magness, A. Rowan, A. Karamani, B. Chain, B. B. Campbell, C. Castignani, C. E. Weeden et al., Nature 2023, 616, 525.
A. Sharma, D. Shambhwani, S. Pandey, J. Singh, H. Lalhlenmawia, M. Kumarasamy, S. K. Singh, D. K. Chellappan, G. Gupta, P. Prasher, K. Dua, D. Kumar, ACS Omega 2022, 8(1), 10.
M. Al Bakir, A. Huebner, C. Martínez‐Ruiz, K. Grigoriadis, T. B. K. Watkins, O. Pich, D. A. Moore, S. Veeriah, S. Ward, J. Laycock, D. Johnson, A. Rowan, M. Razaq, M. Akther, C. Naceur‐Lombardelli, P. Prymas, A. Toncheva, S. Hessey, M. Dietzen, E. Colliver, A. M. Frankell, A. Bunkum, E. L. Lim, T. Karasaki, C. Abbosh, C. T. Hiley, M. S. Hill, D. E. Cook, G. A. Wilson, R. Salgado, E. Nye, R. K. Stone, D. A. Fennell, G. Price, K. M. Kerr, B. Naidu, G. Middleton, Y. Summers, C. R. Lindsay, F. H. Blackhall, J. Cave, K. G. Blyth, A. Nair, A. Ahmed, M. N. Taylor, A. J. Procter, M. Falzon, D. Lawrence, N. Navani, R. M. Thakrar, S. M. Janes, D. Papadatos‐Pastos, M. D. Forster, S. M. Lee, T. Ahmad, S. A. Quezada, K. S. Peggs, P. Van Loo, C. Dive, A. Hackshaw, N. J. Birkbak, S. Zaccaria, J. F. Lester, A. Bajaj, A. Nakas, A. Sodha‐Ramdeen, K. Ang, M. Tufail, M. F. Chowdhry, M. Scotland, R. Boyles, S. Rathinam, C. Wilson, D. Marrone, S. Dulloo, G. Matharu, J. A. Shaw, J. Riley, L. Primrose, E. Boleti, H. Cheyne, M. Khalil, S. Richardson, T. Cruickshank, S. Benafif, K. Gilbert, A. J. Patel, A. Osman, C. Lacson, G. Langman, H. Shackleford, M. Djearaman, S. Kadiri, A. Leek, J. D. Hodgkinson, N. Totten, A. Montero, E. Smith, E. Fontaine, F. Granato, H. Doran, J. Novasio, K. Rammohan, L. Joseph, P. Bishop, R. Shah, S. Moss, V. Joshi, P. Crosbie, F. Gomes, K. Brown, M. Carter, A. Chaturvedi, L. Priest, P. Oliveira, M. G. Krebs, A. Clipson, J. Tugwood, A. Kerr, D. G. Rothwell, E. Kilgour, H. J. W. L. Aerts, R. F. Schwarz, T. L. Kaufmann, R. Rosenthal, Z. Szallasi, J. Kisistok, M. Sokac, M. Diossy, J. Demeulemeester, A. Stewart, A. Magness, A. Karamani, B. Chain, B. B. Campbell, C. Castignani, C. Bailey, C. Puttick, C. E. Weeden, C. Lee, C. Richard, D. R. Pearce, D. Karagianni, D. Biswas, D. Levi, E. Hoxha, E. Larose Cadieux, E. Grönroos, F. Gálvez‐Cancino, F. Athanasopoulou et al., Nature 2023, 616, 534.
Y. Cheng, T. Zhang, Q. Xu, MedComm 2021, 2(4), 692.
B. Aslan, B. Ozpolat, A. K. Sood, G. Lopez‐Berestein, J. Drug. Target. 2013, 21(10), 904.
P. Kumari, B. Ghosh, S. Biswas, J. Drug. Target. 2016, 24(3), 179.
A. Zielińska, F. Carreiró, A. M. Oliveira, A. Neves, B. Pires, D. N. Venkatesh, A. Durazzo, M. Lucarini, P. Eder, A. M. Silva, A. Santini, E. B. Souto, Molecules 2020, 25(16), 3731.
T. Dou, J. Wang, C. Han, X. Shao, J. Zhang, W. Lu, Int. J. Biol. Macromol. 2019, 138, 791.
F. Croisier, C. Jérôme, Eur. Polym. J. 2013, 49(4), 780.
M. Mohammed, J. Syeda, K. Wasan, E. Wasan, Pharmaceutics 2017, 9(4), 53.
V. Sanna, N. Pala, M. Sechi, Int. J. Nanomed. 2014, 15, 467.
J. L. Spratlin, R. B. Cohen, M. Eadens, L. Gore, D. R. Camidge, S. Diab, S. Leong, C. O'Bryant, L. Q. M. Chow, N. J. Serkova, N. J. Meropol, N. L. Lewis, E. G. Chiorean, F. Fox, H. Youssoufian, E. K. Rowinsky, S. G. Eckhardt, J. Clin. Oncol. 2010, 28(5), 780.
O. Arrieta, Z. L. Zatarain‐Barrón, A. F. Cardona, A. Carmona, M. Lopez‐Mejia, Expert Opin. Drug Saf. 2017, 16(5), 637.
M. Javle, E. C. Smyth, I. Chau, Clin. Cancer Res. 2014, 20(23), 5875.
L. Fan, W. Wang, Z. Wang, M. Zhao, Nat. Commun. 2021, 12(1), 6371.
J. Yao, Z. Yang, L. Huang, C. Yang, J. Wang, Y. Cao, L. Hao, L. Zhang, J. Zhang, P. Li, Z. Wang, Y. Sun, H. Ran, Adv. Sci. 2021, 8(19), 2100850.
Z. Yang, J. Yao, J. Wang, C. Zhang, Y. Cao, L. Hao, C. Yang, C. Wu, J. Zhang, Z. Wang, H. Ran, Y. Tian, Biomater. Sci. 2021, 9(16), 5652.
K. Young, E. Smyth, I. Chau, Therap. Adv. Gastroenterol. 2015, 8(6), 373.
E. De Luca, D. Marino, M. Di Maio, Cancer Manag. Res. 2020, 12, 3721.
H. Verdaguer, J. Tabernero, T. Macarulla, Ther. Adv. Med. Oncol. 2016, 8(3), 230.
G. Vlahovic, A. M. Ponce, Z. Rabbani, F. K. Salahuddin, L. Zgonjanin, I. Spasojevic, Z. Vujaskovic, M. W. Dewhirst, Br. J. Cancer 2007, 97(6), 735.
Z. Yao, J. Zhang, B. Zhang, G. Liang, X. Chen, F. Yao, X. Xu, H. Wu, Q. He, L. Ding, B. Yang, Pharmacol. Res. 2018, 133, 121.
N. H. Hoang, T. Le Thanh, R. Sangpueak, J. Treekoon, C. Saengchan, W. Thepbandit, N. K. Papathoti, A. Kamkaew, N. Buensanteai, Polymers 2022, 14(4), 662.
V. Kafil, M. Eskandani, Y. Omidi, H. Nazemiyeh, J. Barar, RSC Adv. 2015, 5(23), 18041.
E. Brauchle, S. Thude, S. Y. Brucker, K. Schenke‐Layland, Sci. Rep. 2014, 4(1), 4698.
C. Sandt, J. Waeytens, A. Deniset‐Besseau, C. Nielsen‐Leroux, A. Réjasse, Spectrochim. Acta, Part A 2021, 258, 119841.
A. Vijayan, S. A., G. S. V. Kumar, Sci. Rep. 2019, 9(1), 19165.
A. Derenne, K.‐M. Derfoufi, B. Cowper, C. Delporte, E. Goormaghtigh, Anal. Chim. Acta 2020, 1112, 62.
Z. Karimi Ghezeli, M. Hekmati, H. Veisi, Appl. Organomet. Chem. 2019, 33(4), e4833.
L. Hasandoost, A. Akbarzadeh, H. Attar, A. Heydarinasab, Artif. Cells, Nanomed., Biotechnol. 2017, 45(3), 665.
M. J. Patoliya, G. J. Kharadi, J. Chem. 2013, 2013, 1.
F. F. An, W. Cao, X. J. Liang, Adv. Healthcare Mater. 2014, 3(8), 1162.
P. Fotouhi, S. Sohrabi, N. Nosrati, A. Z. Vaziri, S. Khaleghi, A. Narmani, H. Jafari, J. Mohammadnejad, Process Biochem. 2021, 111, 221.
S. Bhullar, N. Goyal, S. Gupta, Sci. Rep. 2022, 12(1), 4600.
L. Pandolfi, R. Fusco, V. Frangipane, R. D'Amico, M. Giustra, S. Bozzini, M. Morosini, M. D'Amato, E. Cova, G. Ferrario, P. Morbini, M. Colombo, D. Prosperi, S. Viglio, D. Piloni, R. Di Paola, S. Cuzzocrea, F. Meloni, Sci. Rep. 2020, 10(1), 20726.
D. Uprety, Biologics: Target. Ther. 2019, 13, 133.
Amin M. K., Boateng J. S. Marine Drugs. 2022, 20(3):156.